Aug 25 (Reuters) - Royalty Pharma ( RPRX ) said on

Monday it has signed a deal with BeOne Medicines to acquire a

royalty interest in Amgen's ( AMGN ) drug for small cell lung

cancer for up to $950 million.

The deal gives Royalty Pharma ( RPRX ) access to roughly 7% of global

net sales of the therapy, which won U.S. approval last year for

patients with extensive-stage small cell lung cancer who have

failed chemotherapy.